TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells

TRAIL induces apoptosis in cancer cells whilst sparing normal tissues. Despite promising pre-clinical results, few patients responded to treatment with recombinant TRAIL (Apo2L/Dulanermin) or TRAIL-R2-specific antibodies, such as conatumumab (AMG655). It is unknown whether this was due to intrinsic...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncogene
Huvudupphovsmän: Tuthill, Mark H, Montinaro, Antonella, Zinngrebe, Julia, Prieske, Katharina, Draber, Peter, Prieske, Stefan, Newsom-Davis, Tom, von Karstedt, Silvia, Graves, Jonathan, Walczak, Henning
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2014
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4240732/
https://ncbi.nlm.nih.gov/pubmed/24909167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2014.156
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk